Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?

[1]  S. Chiaretti,et al.  Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Patel,et al.  Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1 , 2023, American journal of hematology.

[3]  J. Stuchly,et al.  Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease , 2022, Leukemia.

[4]  F. Gao,et al.  The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. , 2022, Blood.

[5]  M. Konopleva,et al.  High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse , 2022, Blood advances.

[6]  N. Darzentas,et al.  Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods , 2022, Blood advances.

[7]  R. Foà,et al.  Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia , 2021, Hematological oncology.

[8]  M. Konopleva,et al.  Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors , 2021, Cancer.

[9]  A. Logan,et al.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts , 2018, American journal of hematology.

[10]  L. Anelli,et al.  Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia. , 2018, The Journal of molecular diagnostics : JMD.

[11]  M. Loh,et al.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. , 2018, Blood.

[12]  R. Pieters,et al.  Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor a , 2017, Haematologica.

[13]  D. Berry,et al.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis , 2017, JAMA oncology.

[14]  M. Trková,et al.  Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. , 2017, Blood.

[15]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.